Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(16):1416-1417; doi:10.1093/jnci/91.16.1416
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Messing, E. M.
Right arrow Articles by Wilding, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Messing, E. M.
Right arrow Articles by Wilding, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 16, 1416-1417, August 18, 1999
© 1999 Oxford University Press

BRIEF COMMUNICATION

Low-Dose Difluoromethylornithine and Polyamine Levels in Human Prostate Tissue

Edward M. Messing, Richard R. Love, Kendra D. Tutsch, Ajit K. Verma, Jeffrey Douglas, Marcia Pomplun, Ruby Simsiman, George Wilding

Affiliations of authors: E. M. Messing, Department of Urology, University of Rochester Medical Center, NY; R. R. Love, K. D. Tutsch, M. Pomplun, G. Wilding (Section of Medical Oncology, Department of Medicine), A. K. Verma, R. Simsiman (Department of Human Oncology), J. Douglas (Department of Biostatistics and Informatics), University of Wisconsin School of Medicine, Madison.

Correspondence to: Richard R. Love, M.D., 1300 University Ave., 7C MSC, Madison, WI 53706.

Difluoromethylornithine is a noncompetitive inhibitor of ornithine decarboxylase, which catalyzes the rate-limiting step in polyamine synthesis. Induction of ornithine decarboxylase activity has been closely associated with the action of tumor promoters (1,2), growth factors (3,4), and mitogenic hormones (5-7). Difluoromethylornithine inhibits the development of spontaneous and carcinogen-induced mammalian tumors in vivo, including carcinomas of the breast, colon, epidermis, and bladder (8-11). At low difluoromethylornithine doses of 0.5 g/m2 or less given by mouth daily, polyamine suppression has been demonstrated in skin and colonic tissues (12-14), with limited and reversible toxicity (13,14). The prostate gland is of particular . . . [Full Text of this Article]

NOTES

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A.-T. Vlastos, L. A. West, E. N. Atkinson, I. Boiko, A. Malpica, W. K. Hong, and M. Follen
Results of a Phase II Double-Blinded Randomized Clinical Trial of Difluoromethylornithine for Cervical Intraepithelial Neoplasia Grades 2 to 3
Clin. Cancer Res., January 1, 2005; 11(1): 390 - 396.
[Abstract] [Full Text] [PDF]